Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about leveraging point-of-care marketing momentum and its influence on decision making and how does Doceree maintain contextual relevance in marketing on a national scale.
Outlook Therapeutics faces FDA hurdles for Lytenava's approval in wet AMD, seeking clarity on efficacy requirements while expanding globally.
Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about the role of AI in programmatic marketing, and the expectations of developments in communication between healthcare professionals and pharmaceutical brands.
Replicate Bioscience partners with Novo Nordisk to advance self-replicating RNA therapies for obesity and type 2 diabetes, enhancing innovative treatment options.
Amylyx Pharmaceuticals halts Amx0035's Orion program for PSP, shifting focus to Avexitide and other promising treatments for neurodegenerative diseases.
Bayer's Gadoquatrane, a low-dose MRI contrast agent, aims to enhance imaging safety and efficacy for chronic disease patients, pending FDA approval.
ACOG reaffirms support for COVID-19 vaccines during pregnancy, challenging recent CDC recommendations and emphasizing maternal and fetal health.
Pfizer initiates layoffs at its Bothell site as part of a broader cost-cutting strategy, aiming to enhance R&D efficiency and automation.
Eli Lilly's oral GLP-1 receptor agonist Orforglipron showed significant weight loss, A1C reduction, and cardiometabolic improvements in the Phase III Attain-2 trial, paving the way for global regulatory submissions.
Genentech broke ground on a $700 million manufacturing facility in Holly Springs, North Carolina its first on the U.S. East Coast supporting next-generation obesity treatments and metabolic medicines as part of Roche’s broader $50 billion U.S. investment in innovation, job creation, and advanced biomanufacturing.
The CDC appointed Retsef Levi, a vocal critic of mRNA Covid-19 vaccines, to lead its Covid-19 immunization workgroup, a panel tasked with reviewing vaccine safety and effectiveness, despite controversy surrounding his past calls for vaccine withdrawal.
BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of Imdelltra, securing an $885 million upfront payment and potential additional royalties, while retaining rights to other pipeline assets and future high-sales milestones.
The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple hospitalizations, and deaths linked to chikungunya-like illness.
Lighthouse Pharmaceuticals receives a $49.2 million grant from the National Institute on Aging, aimed at advancing a Phase 2 clinical trial of LHP588, a novel gingipain inhibitor targeting Porphyromonas Gingivalis, aimed at slowing Alzheimer's progression in infected patients by addressing a potential microbial cause of neuroinflammation and neurodegeneration
Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea HD due to a major amendment stemming from a third-party manufacturing inspection. Despite the delay, Eylea HD remains available in the U.S., and Regeneron anticipates a swift resolution as they address manufacturing concerns and continue expanding treatment options.
Johnson & Johnson assures no impact on current treatments for multiple myeloma.
Jazz Pharmaceuticals partners with Saniona to develop SAN2355, a promising epilepsy treatment, enhancing options for neurological disorders.
The AAP diverges from CDC guidelines, advocating for Covid-19 vaccines in young children, igniting debate over vaccine policy and public health integrity.
Monument Therapeutics partners with FNIH to advance MT1988, a promising treatment for cognitive impairment in schizophrenia, through a groundbreaking clinical trial.
Whole genome sequencing market is projected to grow significantly, driven by advancements in technology and personalized medicine, reaching $6.1 billion by 2030.
Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment and ensuring patient safety.
NIH's new strategy emphasizes transparency, prioritizes urgent health needs, and shifts focus to domestic research and innovative health solutions.
Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains committed to future treatments.
Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and cardiometabolic diseases, aiming for innovative treatments.
Eli Lilly partners with the Indiana Fever and YMCA to empower girls in basketball, removing barriers and promoting community engagement in sports.
Connect Biopharma partners with the Jovante Woods Foundation to enhance asthma education and awareness, aiming to prevent acute attacks and save lives.
Seal Rock Therapeutics joins The Michael J. Fox Foundation's LITE program to help advance research and developments in inhibitors targeting LRRK2 in Parkinsons disease.
Oikos Fusion offers a nutrient-dense dairy drink designed to support muscle mass and digestive health during weight loss journeys.
Monica Seles partners with argenx to raise awareness for Myasthenia Gravis, sharing her journey to empower and support those affected by the condition.
Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet medical needs in oncology.
